A therosclerotic cardiovascular disease (CVD) is a leading cause of morbidity and mortality in developed countries.
A therosclerotic cardiovascular disease (CVD) is a leading cause of morbidity and mortality in developed countries. 1, 2 Although high-density lipoproteins (HDL) represent a protective factor, both increased plasma levels of cholesterol within apolipoprotein B (apoB)-containing lipoproteins and inflammation causally contribute to the pathogenesis of atherosclerosis. 3, 4 The latter is further illustrated by various acute phase proteins having a predictive value for future cardiovascular events. [3] [4] [5] Among these, plasma levels and activity of the acute phase protein type IIA secretory phospholipase A 2 (sPLA 2 -IIA) have been demonstrated to predict coronary events in selected patients with coronary artery disease [6] [7] [8] [9] [10] and in the general population. 11, 12 In mouse models, transgenic (tg) human sPLA 2 -IIA expression has several proatherosclerotic properties, such as decreased plasma HDL levels because of increased catabolism, [13] [14] [15] formation of aggregated/fused low-density lipoprotein (LDL), 16 increased LDL oxidation, 17, 18 and induction of severe endothelial dysfunction. 19 These effects actually translate into significant atherosclerotic lesion formation in human sPLA 2 -IIA tg mice, even on a chow diet. 20 Taken together, these proatherogenic features of sPLA 2 -IIA suggest that pharmacological inhibition of this enzyme might represent a therapeutic strategy against atherosclerotic CVD targeting both the lipoprotein component and the inflammatory component of atherogenesis. Indeed, in animal models, sPLA 2 inhibition showed a reduction in atherosclerotic lesion formation. 21 However, in contrast to the consistent results in preclinical models, clinical trials using sPLA 2 inhibitors reveal no HDL-raising effect. 21 The underlying mechanistic basis for these unexpected differences between animal models and humans is currently unclear. Therefore, the aim of this study was to investigate the effect of inhibiting the enzymatic activity of sPLA 2 -IIA in a novel humanized tg mouse model of atherosclerosis, December 2013 hsPLA 2 -IIA/ human apoB (hapoB)/human cholesteryl ester transfer protein (CETP) triple tg mice (TTT). Our results demonstrate that inhibition of sPLA 2 -IIA activity does not alter atherosclerotic lesion formation in this mouse model probably because it induced a proatherogenic plasma lipoprotein profile. In additional experiments we delineated the potential underlying mechanism, namely that sPLA 2 -IIA decreased CETP activity because of a decrease in the apoE content of sPLA 2 -IIA-modified very low-density lipoprotein (VLDL) particles. On sPLA 2 -IIA inhibition, CETP activity increased resulting in elevated plasma levels of proatherogenic apoB-containing lipoproteins. In a clinical perspective, these experimental data suggest that in patients with stable CVD sPLA 2 -IIA inhibition in combination with a statin or eventually also a CETP inhibitor to decrease VLDL/LDL cholesterol might represent a valid therapeutic approach.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results
sPLA 2 -IIA Inhibition Efficiently Reduces Plasma sPLA 2 -IIA Activity, but Not Atherosclerosis, in TTT Mice Addition of the sPLA 2 -IIA inhibitor to the diet resulted in a marked decrease in plasma sPLA 2 activity in the TTT mice indicating efficient inhibition of the enzyme (400±50 versus 30±5 U/L; P<0.001). Plasma levels of sPLA 2 -IIA as determined by ELISA also decreased (581±300 versus 114±35 µg/ mL; P<0.001).
Introducing the human sPLA 2 -IIA transgene into hapoB/ hCETP double tg mice resulted in increased atherosclerotic lesion formation determined either as total plaque area (P<0.01; Figure 1A ) or as oil-red-O-positive-stained area (P<0.05; Figure 1B ). These results are consistent with a proatherosclerotic role of sPLA 2 -IIA previously described in single tg mice.
20 Surprisingly, however, administration of the sPLA 2 -IIA inhibitor did not change atherosclerotic lesion formation in the TTT mice evaluated in whole aorta, brachiocephalic artery, and aortic root sections after oil-red staining ( Figure 1A and 1B) . Representative aortic root sections are shown in Figure 1C . Dyslipidemia and inflammation are major contributing factors to atherogenesis. 3, 4 To explain the surprising findings of sPLA 2 -IIA inhibition on atherosclerotic lesion formation, we first evaluated the effect on plasma lipid and lipoprotein profiles. Plasma total cholesterol ( Figure 2A ) and triglyceride ( Figure  2B ) levels were not different between hapoB/hCETP double tg mice and TTT mice. However, administration of the sPLA 2 -IIA inhibitor resulted in a significant increase in plasma total cholesterol levels in the TTT mice (P<0.05; Figure 2A ) and a trend toward higher levels for plasma triglycerides (P<0.09; Figure 2B ). Feeding the sPLA 2 -IIA inhibitor to hapoB/ hCETP double tg mice had essentially no effect on plasma total cholesterol or triglycerides ( Figure I in the online-only Data Supplement) indicating that the changes in plasma lipids were related to sPLA 2 sPLA 2 -IIA expression in TTT compared with hapoB/hCETP double tg mice on Western diet ( Figure 2C ). However, sPLA 2 inhibition in TTT resulted in increased plasma cholesterol levels within the apoB-containing lipoproteins VLDL (P<0.001; Figure 2C ) and LDL (P<0.01; Figure 2C ) and decreased levels of HDL cholesterol (P<0.001; Figure 2C ). The VLDL phospholipid content was increased on varespladib acid treatment in TTT to a similar extent as the VLDL cholesterol levels (0.08±0.03 versus 0.48±0.24; P<0.01). These data demonstrate that inhibition of sPLA 2 -IIA results in a proatherogenic plasma lipoprotein profile specifically in the functional context of CETP expression.
sPLA 2 -IIA Expression Decreases Plasma CETP Activity
Because the changes in the plasma lipoprotein profile induced by sPLA 2 inhibition closely resemble alterations because of increased CETP activity, we hypothesized that sPLA 2 -IIA expression might inhibit CETP activity. Consistent with this hypothesis, CETP activity decreased in hCETP/hapoB double tg mice when the hsPLA 2 -IIA transgene was also expressed (38.1±19.7 versus 13.3±10.1 pmol/h; P<0.01; Figure 3 ). Interestingly, inhibition of sPLA 2 -IIA with varespladib acid resulted in a striking 7-fold increase in CETP activity compared with TTT treated with vehicle (69.4±21.1 pmol/h; P<0.001; Figure 3 ). The inhibitory effect of sPLA 2 -IIA on plasma CETP activity was independent of the atherogenic diet as evidenced by significantly lower plasma CETP activity in chow-fed TTT compared with chow-fed hapoB/ hCETP double tg mice (P<0.05; Figure IV in the onlineonly Data Supplement). However, the inhibitor varespladib acid had no effect on plasma CETP activity in the absence of sPLA 2 -IIA in hapoB/hCETP double tg mice ( Figure II in the online-only Data Supplement). This indicates that the observed increase in CETP activity, after varespladib acid administration, is because of inhibition of sPLA 2 -IIA activity.
These data demonstrate that sPLA 2 -IIA expression results in decreased CETP activity.
sPLA 2 -IIA Inhibition Increases the Acceptor Properties of VLDL for CETPMediated Lipid Transfer in TTT Mice
Next, we investigated whether the differences in plasma CETP activity observed between TTT mice treated with either varespladib acid or vehicle might be because of different amounts of CETP protein present in plasma. As determined by Western blot, plasma CETP protein levels were identical in both groups (varespladib acid: 4.49±1.47 mg/L versus vehicle: 4.22±1.55 mg/L; ns; Figure 4A ), indicating that administration of Type IIA secretory phospholipase A2 (sPLA 2 -IIA) inhibition increases cholesteryl ester transfer protein (CETP) activity in vivo. CETP activity was assayed as described under Methods in the online-only Data Supplement in plasma from human CETP/ human apolipoprotein B (apoB) double transgenic mice (TT) as well as in plasma from human CETP/human apoB/human sPLA 2 -IIA triple transgenic mice (TTT) fed a Western-type diet containing either vehicle or the specific sPLA 2 -IIA inhibitor varespladib acid (+VA). Data are given as mean±SD. n=10 in each group. a indicates statistically significant differences from the TT; b, statistically significant differences from the TTT; and c, statistically significant differences from the TTT+VA group (at least P<0.05).
varespladib acid does not affect plasma CETP protein levels but results in a selective increase in CETP activity.
Because plasma CETP activity is influenced by the properties of apoB-containing lipoproteins and HDL to serve as acceptors and donors of cholesterol, respectively, we next differentially explored these features using lipoprotein subclasses isolated by ultracentrifugation from TTT treated with varespladib acid or vehicle. On incubation with fixed amounts of exogenous purified CETP, CETP activity was significantly higher, when VLDL (P<0.05; Figure  4B ) or LDL (P<0.05; Figure 4C ) from TTT treated with the sPLA 2 -IIA inhibitor varespladib acid was added to the assay compared with apoB-containing lipoproteins from vehicle-treated TTT. However, although sPLA 2 -IIA expression results in major changes in HDL composition, 13, 22 the donor properties of HDL isolated from TTT with and without varespladib acid treatment were not affected (ns; Figure  4D ). Using the infranatant as CETP source and exogenous donor and acceptor liposomes, CETP activities were identical, when TTT receiving the inhibitor were compared with those that were vehicle treated (ns; Figure 4E ). These data are consistent with the unchanged plasma CETP protein levels in both groups of mice.
Taken together, these results indicate that sPLA 2 -IIA expression might specifically decrease the acceptor properties of VLDL for CETP-mediated lipid transfer translating into reduced plasma CETP activity. To distinguish whether the observed alterations in the cholesterol content of the different lipoprotein subclasses in response to sPLA 2 -IIA inhibition represent the underlying cause or the consequence of increased plasma CETP activity, human sPLA 2 -IIA single tg mice that lack endogenous or transgenically expressed CETP were placed on a Western-type diet and treated with either the sPLA 2 -IIA inhibitor varespladib acid or vehicle. In contrast to the TTT mice expressing CETP, treatment with varespladib acid did not affect cholesterol content of VLDL (ns; Figure 5A ), whereas LDL (P<0.05; Figure 5A ) and HDL (P<0.05; Figure 5A ) cholesterol contents were increased compared with vehicle-treated mice. The latter data are consistent with sPLA 2 -IIA expression resulting in decreased plasma HDL cholesterol levels because of increased catabolism. 13, 14 The triglyceride (TG):protein ratio remained unchanged within VLDL (0.804±0.198 versus 0.771±0.256, respectively; ns) and LDL (0.329±0.042 versus 0.338±0.165, respectively; ns) from mice receiving varespladib acid compared with vehicle treatment, whereas being decreased within HDL (0.058±0.013 versus 0.079±0.012, respectively; P<0.05). The TG:cholesterol ratio of VLDL (1.272±0.555 versus 1.866±0.704, respectively; ns), LDL (0.178±0.019 versus 0.183±0.087, respectively; ns), and HDL (0.081±0.016 versus 0.090±0.017, respectively; ns) was also not affected by varespladib acid compared with vehicle treatment. In addition, also the phospholipid content of VLDL was identical between the 2 groups (0.031±0.009 versus 0.028±0.010 mmol/L; ns), and the phospholipid:cholesterol ratio remained unaffected by varespladib acid administration (0.745±0.081 versus 0.778±0.065; ns). These data indicate that the altered cholesterol and phospholipid contents within VLDL of varespladib acid-treated TTT are a consequence of increased CETP activity rather than its cause.
Next, CETP activity assays were performed with purified CETP, testing VLDL, LDL, and HDL for their ability to interact with purified CETP. Interestingly, CETP activity was 2.8-fold higher when VLDL from single sPLA 2 -IIA tg mice treated with varespladib acid was used compared with VLDL from mice receiving vehicle (P<0.01; Figure 5B ). In addition, there was no impact of cholic acid in the diet on the acceptor properties of VLDL from sPLA 2 -IIA single tg mice because VLDL isolated from chow-fed versus 0.5% cholic acid-fed mice gave comparable results in CETP transfer assays (Figure V in the onlineonly Data Supplement). However, there were no differences on the substrate properties of LDL (ns; Figure 5C ) and HDL (ns; Figure 5D ) when lipoproteins isolated from varespladib acid-treated mice and controls were compared. These data confirm that even in the absence of altered VLDL lipid composition the cholesterol acceptor function of sPLA 2 -IIA-modified VLDL for CETP-mediated transfer is severely impaired translating into significantly decreased plasma CETP activity.
Because the lipid composition of sPLA 2 -IIA-modified VLDL did not represent the underlying basis for decreased CETP activity, we next determined the protein composition of VLDL using SDS-PAGE followed by silver staining. VLDL isolated from sPLA 2 -IIA tg mice receiving vehicle showed a significantly decreased band in the molecular weight range of apoE (data not shown) as the only difference, when compared with VLDL from varespladib acid-treated sPLA 2 -IIA tg mice. Subsequently, a striking 3.4-fold increase (P<0.05) in the apoE content of VLDL isolated from sPLA 2 -IIA inhibitor-treated single tg mice was confirmed by Western blot using lipoproteins isolated by ultracentrifugation ( Figure 5E of CETP activity by facilitating the binding of CETP to VLDL particles. 23 Taken together, these data suggest that decreased VLDL-apoE content is the major metabolic change induced by sPLA 2 -IIA activity subsequently resulting in decreased plasma CETP activity. By the use of the sPLA 2 inhibitor varespladib acid, this effect is reversed leading to a substantial increase in CETP activity and consequently a proatherogenic plasma lipid and lipoprotein profile in the TTT mouse model.
Hepatic ApoE Overexpression in sPLA 2 -IIA Single tg Mice Increases the VLDL-ApoE Content and Subsequently the Acceptor Properties for CETP
Next, apoE was overexpressed in livers of sPLA 2 -IIA tg mice by means of a recombinant adenovirus to establish that increasing the apoE content of VLDL in this model translates into increased CETP activity. ApoE overexpression did not affect plasma sPLA 2 -IIA activity (537±83 versus 515±54 U/L). VLDL particles isolated from sPLA 2 -IIA single tg mice on day 3 after injection with AdhapoE3 were 1.4-fold enriched in apoE compared with VLDL from control adenovirus-administered mice (P<0.05; Figure 6A ). Consistent with our hypothesis, CETP activity was significantly increased when VLDL from sPLA 2 -IIA tg mice injected with the apoEexpressing adenovirus was used as acceptor particles for CETP-mediated transfer compared with VLDL from controls (P<0.01; Figure 6B ). These data demonstrate that increasing the VLDL-apoE content improves the acceptor properties of VLDL from sPLA 2 -IIA tg mice for CETP-mediated transfer translating into increased CETP activity.
Discussion
Based on evidence that the acute phase protein sPLA 2 -IIA is a cardiovascular risk factor [6] [7] [8] [9] [10] [11] [12] with intrinsic proatherosclerotic biological activity, 24, 25 specific inhibition of sPLA 2 -IIA activity in vivo seems to be an attractive target for the treatment of atherosclerotic CVD. As opposed to consistent data in preclinical models supporting this concept, 21 clinical trials conducted with the sPLA 2 inhibitor varespladib did not deliver the desired antiatherosclerotic results, leading to the discontinuation of the further clinical development of this drug. 26 The present study tested the effect of sPLA 2 -IIA inhibition in a novel humanized mouse model of lipoprotein metabolism, human apoB/human CETP/human sPLA 2 -IIA triple tg mice (TTT) fed a cholesterol-containing diet. However, when TTT were given the sPLA 2 -IIA inhibitor varespladib acid there was no impact on atherosclerosis, probably because of the development of a proatherogenic plasma lipoprotein profile with increased apoBcontaining lipoproteins and decreased HDL. The latter result was especially unexpected because tg sPLA 2 -IIA expression in wild-type mice has a strong decreasing effect on plasma HDL levels by increasing the HDL catabolic rate. [13] [14] [15] The changes in the plasma lipoprotein profile after administration of varespladib acid were consistent with increased plasma CETP activity. Subsequently, our data confirmed that inhibition of sPLA 2 -IIA resulted in a marked increase in plasma CETP activity in the TTT group. Increased CETP activity has been linked to increased risk for atherosclerotic CVD in human populations. 27, 28 CETP activity in vivo mainly depends on 2 factors: (1) the plasma concentration of the CETP protein and (2) the quantity and the quality of the lipoprotein substrates. 29, 30 The large increase in CETP activity after sPLA 2 -IIA inhibition could not be explained by changes in plasma CETP mass levels, as shown by quantitative Western blot and by the unchanged cholesteryl ester transfer activity measured in plasma infranatants devoid of lipoproteins. Instead, our data demonstrate that increased CETP activity on sPLA 2 -IIA inhibition was because of an enhanced ability of VLDL to serve as cholesteryl ester acceptors in the presence of purified CETP and liposome donors, whereas LDL and HDL substrate properties were only slightly or not at all modified. The increased ability of VLDL from TTT treated with the sPLA 2 -IIA inhibitor to interact with CETP was accompanied by a cholesterol enrichment of the VLDL fraction. Although some studies demonstrated that VLDL cholesterol content can have an impact on the magnitude of the CETP-mediated neutral lipid exchange between lipoproteins, [31] [32] [33] we observed a similar improvement of VLDL acceptor properties after sPLA 2 -IIA inhibition, when VLDL from hsPLA 2 single tg mice lacking CETP was used that displayed identical cholesterol content within VLDL. These results demonstrate that (1) compared with vehicle-treated sPLA 2 -IIA single tg mice the dramatic cholesterol enrichment of VLDL from TTT treated with the sPLA 2 -IIA inhibitor is a consequence rather than the cause of increased CETP activity and (2) the increased ability of VLDL to interact with CETP after sPLA 2 -IIA inhibition is not because of alterations of the lipid composition of VLDL but possibly because of a modification of the protein composition of the particles.
We think that the finding that altered protein composition of VLDL represents the underlying basis of changes in Figure 6 . Increasing the VLDL-apolipoprotein E (apoE) content improves the acceptor properties of Type IIA secretory phospholipase A2 (sPLA 2 -IIA)-modified VLDL. sPLA 2 -IIA transgenic mice were fed a Western-type diet and then injected with either the control adenovirus AdNull or the apoE-expressing adenovirus AdhapoE3. On day 3 after injection, VLDL was isolated and cholesteryl ester transfer protein (CETP) activity assays were performed as detailed in Methods in the online-only Data Supplement. A, Western blot for total apoE content within the VLDL fraction on day 3 after injection of the respective adenoviruses. B, CETP activity determined using as acceptors VLDL from mice injected with the respective adenoviruses as indicated. Data are given as mean±SD. n=6 in each group. *Significantly different from AdNull-injected controls (at least P<0.05).
CETP activity in vivo is a novel observation because most studies published today focused on the protein composition and related cholesterol donor properties of HDL. Indeed, the impact of apoA-I, apoA-II, and apoC-I content was studied in HDL, 34, 35 and the influence of the Lipid Transfer Inhibitor Protein, also known as apoF, was investigated in LDL and HDL. 34, 35 As judged from silver-stained SDS-PAGE gels, the only significant difference between VLDL from sPLA 2 inhibitor-treated mice and control animals was a striking increase in the apoE content in mice receiving the inhibitor. When the VLDL-apoE content was increased in sPLA 2 -IIA single tg mice by means of adenovirus-mediated gene transfer, the CETP acceptor properties of these particles were significantly improved. These data are in line with a case study on VLDL from a single apoE-deficient subject that reported lower CETP activity using the apoE-deficient VLDL as acceptor compared with VLDL from controls. 23 The potential physiological role of an inhibition of CETP by the acute phase protein sPLA 2 -IIA has not been explored in the present study. Although largely speculative, we think that one possibility is that inflammatory conditions require increased synthesis of steroid hormones and that HDL cholesteryl ester is a known source of cholesterol for steroid hormone synthesis. 36 sPLA 2 -IIA could make HDL cholesteryl ester more accessible to steroidogenic tissues by increasing SR-BI-mediated selective uptake. 13, 14 Although inflammation already downregulates CETP expression, 37 additional inhibition of CETP by sPLA 2 -IIA in this context might further increase the availability of HDL cholesteryl ester for steroid hormone synthesis and might thus represent a protective mechanism during the host response. In this context, it might be important to point out that the cholate added to the diet in our present study induces a certain degree of hepatic inflammation, as shown in Table I in the online-only Data Supplement. However, based on several additional control experiments that we performed, we do not think that this dietary choice affected the validity of our results.
The lack of an HDL-raising effect on sPLA 2 -IIA inhibition in patients contrasts the biological effects that would be predicted to occur on sPLA 2 -IIA inhibition. 13, 21, 38 Experiments in mice showed that the predominant phenotype of tg expression of human sPLA 2 -IIA on the C57BL/6 genetic background is decreased plasma HDL cholesterol because of an increased catabolic rate. 13, 14 In support of this mechanism, sPLA 2 inhibition in our present study significantly increased plasma HDL cholesterol in a CETP-deficient model. In mice expressing CETP, however, inhibition of CETP by sPLA 2 -IIA expression did not result in a beneficial effect on the plasma lipoprotein profile. Conceivably, a potential HDL-raising effect is counteracted by the direct impact sPLA 2 -IIA has independent of CETP by increasing HDL catabolism and thereby decreasing plasma HDL-C levels. In the same direction, a decrease in the apoE content of apoB-containing lipoproteins would be expected to decrease their catabolic rate and thereby counteract a potential decrease in the plasma levels of these lipoproteins caused by the inhibition of CETP.
High-risk patients with atherosclerotic CVD and a significant inflammatory load have increased plasma levels of sPLA 2 -IIA 6, 7, 19 and for this patient group sPLA 2 -IIA inhibitors have been developed. 38 However, in stable patients with CVD, no HDL cholesterol increase was observed. 21 Our data suggest that modulation of CETP activity might be the mechanistic basis for this observation. However, our data have been generated in a mouse model with all the potential limitations, so that still validation in a human setting would be required. Although a prospective trial in patients with acute coronary syndrome was discontinued because of lack of efficacy of the sPLA 2 -IIA inhibitor varespladib, 26 in our view a clinical trial with sufficient duration to investigate atherosclerosis-mediated cardiovascular events in stable patients with CVD combining a sPLA 2 -IIA inhibitor with a statin and potentially also with a CETP inhibitor, once a compound with proven clinical benefit becomes available, would still provide scientifically valuable information.
In conclusion, the results from this study performed in a tg humanized mouse model with hypercholesterolemia show proatherogenic effects of sPLA 2 -IIA inhibition on the plasma lipoprotein profile that might counteract the local antiatherogenic effects in the vessel wall.
